Roger Waltzman

Roger Waltzman

Company: Molecular Templates

Job title: Chief Medical Officer

Seminars:

Exploring MT-6402, a Novel Engineered Toxin Body Targeting PD-L1—Interim Data of a Dose Escalation Trial in Patients with Relapsed/Refractory PD-L1-Expressing Solid Tumors 2:30 pm

Read more

day: Day One

Panel Discussion: Exploring the Strategic Challenges of Moving Forward a Drug You Want to Combine with PD-1 in Chemo+PD-1 Progressors 12:30 pm

Understanding the different current comparators and benchmarks Exploring the differences in PD-1 naïve and PD-1 progressors Dissecting why sometimes beating chemo and PD-1 could be an unachievable bar Discussing whether with late-line in-effectivity, how you know it won’t work in early line? Considering the health authorities’ standards on the matterRead more

day: Day One

Investigating Safety & Efficacy of Novel Immunotherapies in Clinical Investigation in NSCLC 12:00 pm

Understanding the translational timeline, patient population and combination rationale Exploring the latest clinical data, challenges and future directions into earlier linesRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.